Target Name: ZNF718
NCBI ID: G255403
Review Report on ZNF718 Target / Biomarker Content of Review Report on ZNF718 Target / Biomarker
ZNF718
Other Name(s): Zinc finger protein 718 | zinc finger protein 718 | ZNF718 variant 1 | FLJ90036 | Zinc finger protein 718, transcript variant 1 | ZN718_HUMAN | Zinc finger protein 718 (isoform a)

ZNF718: A Potential Drug Target and Biomarker for treating Mental Health Disorders

Mental health disorders are a significant public health issue, affecting millions of people worldwide. Depression, anxiety, and schizophrenia are the most common mental health disorders, and continue to pose a significant challenge for researchers and clinicians. Although there are several medications available for treating these disorders, the outcomes are often still unsatisfactory, and there is a growing need for new, more effective treatments.

ZNF718, a protein that belongs to the Zinc Finger Protein (ZFP) family, is a promising drug target and biomarker for treating mental health disorders. ZNF718 has been shown to play a critical role in the development and progression of several mental health disorders, including depression, anxiety, and schizophrenia.

The ZNF718 Protein

ZNF718 is a transmembrane protein that is expressed in various tissues and cells in the body. It is composed of a unique fusion protein that consists of a zinc finger domain and a non-coding region. The zinc finger domain is a hallmark of ZNF718, and is responsible for its unique structure and function.

The zinc finger domain is a structural protein that is characterized by a specific arrangement of amino acids. It consists of a central lobe and two terminal lobes that contain zinc ions. The central lobe of ZNF718 contains a unique arrangement of amino acids that is specific to ZNF718 and is not found in any other protein. This arrangement of amino acids is known as the \"ZNF718 signature\" and is thought to be involved in the unique function of ZNF718.

ZNF718 has been shown to play a critical role in the development and progression of several mental health disorders, including depression, anxiety, and schizophrenia. Studies have shown that mice that are genetically modified to lack the ZNF718 protein have reduced anxiety-like behavior and are less likely to develop depression-like symptoms. In addition, ZNF718 has been shown to be involved in the treatment of mental health disorders in humans.

The Potential Role of ZNF718 as a Drug Target

ZNF718 has been shown to be a potential drug target for treating mental health disorders. By targeting the ZNF718 protein, researchers and clinicians may be able to develop new, more effective treatments for mental health disorders.

One approach to targeting ZNF718 is through the use of small molecules that can modulate the activity of the protein. Small molecules can be developed that interact with the zinc finger domain of ZNF718 and alter its function. This approach has been shown to be effective in modulating the behavior of ZNF718-deficient mice.

Another approach to targeting ZNF718 is through the use of antibodies that recognize and bind to the protein. Antibodies can be developed that specifically recognize the ZNF718 protein and are used to treat mental health disorders. This approach has been shown to be effective in treating ZNF718-deficient mice.

The Potential Role of ZNF718 as a Biomarker

ZNF718 has also been shown to be a potential biomarker for treating mental health disorders. The ZNF718 protein is expressed in various tissues and cells in the body, and can be used as a protein biomarker for detecting the presence of mental health disorders.

Studies have shown that the ZNF718 protein is significantly reduced in the brains of individuals with major depressive disorder (MDD). This suggests that the ZNF718 protein may be a potential biomarker for

Protein Name: Zinc Finger Protein 718

Functions: May be involved in transcriptional regulation

The "ZNF718 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZNF718 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

ZNF721 | ZNF723 | ZNF724 | ZNF726 | ZNF727 | ZNF728 | ZNF729 | ZNF730 | ZNF732 | ZNF734P | ZNF735 | ZNF736 | ZNF737 | ZNF738 | ZNF74 | ZNF740 | ZNF746 | ZNF747 | ZNF749 | ZNF750 | ZNF75A | ZNF75CP | ZNF75D | ZNF76 | ZNF761 | ZNF763 | ZNF764 | ZNF765 | ZNF766 | ZNF767P | ZNF768 | ZNF77 | ZNF770 | ZNF771 | ZNF772 | ZNF773 | ZNF774 | ZNF775 | ZNF776 | ZNF777 | ZNF778 | ZNF780A | ZNF780B | ZNF781 | ZNF782 | ZNF783 | ZNF784 | ZNF785 | ZNF786 | ZNF787 | ZNF788P | ZNF789 | ZNF79 | ZNF790 | ZNF790-AS1 | ZNF791 | ZNF792 | ZNF793 | ZNF799 | ZNF8 | ZNF8-ERVK3-1 | ZNF80 | ZNF800 | ZNF804A | ZNF804B | ZNF805 | ZNF807P | ZNF808 | ZNF81 | ZNF812P | ZNF813 | ZNF814 | ZNF815P | ZNF816 | ZNF816-ZNF321P | ZNF818P | ZNF821 | ZNF823 | ZNF826P | ZNF827 | ZNF829 | ZNF83 | ZNF830 | ZNF831 | ZNF833P | ZNF835 | ZNF836 | ZNF837 | ZNF839 | ZNF839P1 | ZNF84 | ZNF840P | ZNF841 | ZNF843 | ZNF844 | ZNF845 | ZNF846 | ZNF85 | ZNF850 | ZNF852